Analysis shows improved protection against influenza in older adults, indicating high-dose vaccines may reduce disease burden.
Expanding the use of the high-dose vaccine to adults aged 50-64 years may proactively address immunosenescence and enhance protection in this population. Moreover, the development of multicomponent vaccines targeting both influenza and COVID-19 within a single formulation could enhance vaccine uptake and streamline immunization programs. Ultimately, the high-dose vaccine has the potential to replace the standard-dose formulation in older adults, thereby optimizing influenza prevention and reducing disease burden.
No takes yet. Share an insight, caveat, or question.
Trombetta et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: